India’s medical device industry is calling for a more effective framework to regulate trade margins, improve pricing transparency and support healthcare affordability. The demand comes after the National Pharmaceutical Pricing Authority (NPPA) approved a cap on the markup of anti-cancer drugs at 30% of their

